Search | Clinical Trials Finder

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more

Conditions: Glioblastoma
Interventions: Trans Sodium Crocetinate plus SOC, Standard of Care (SOC); Drug · Other
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Irvine, California • Redwood City, California • Santa Monica, California + 10 more

Conditions: Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
Interventions: Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV; Biological · Drug · Radiation
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions: Enpatoran, Placebo, Standard of care (SoC); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 14
States / cities: Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib, 5-Fluorouracil, Cisplatin, Paclitaxel, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Anchorage, Alaska • Duarte, California • Orange, California + 11 more

Conditions: Heart Failure
Interventions: CDR132L, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy; Radiation · Drug · Procedure + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 341
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more

Conditions: Extensive Stage-small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Atezolizumab, Carboplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: TAK-755, Standard of care; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more

Conditions: Glioblastoma
Interventions: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide; Combination Product · Procedure · Drug
Lead sponsor: Imvax; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Jacksonville, Florida • Boston, Massachusetts • Detroit, Michigan + 15 more

Conditions: Solid Tumor, Adult
Interventions: EOS100850, Pembrolizumab, Chemotherapy; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Michigan Center, Michigan • Hackensack, New Jersey • San Antonio, Texas

Conditions: Prevention
Interventions: Stage 1 Strength Based Case Management (SBCM) Condition, Stage 2 PrEPare for Work Intervention Condition; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Providence, Rhode Island

Conditions: Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision; Procedure · Drug · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Multiple Myeloma, Secondary Immunodeficiency
Interventions: IGI, 10%; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more

Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions: Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids; Drug · Procedure
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Post-transplant Lymphoproliferative Disorder
Interventions: Loncastuximab tesirine, Rituximab or rituximab biosimilar; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lymphoma, Non-Hodgkin
Interventions: Standard of Care, JCAR017; Drug · Genetic
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 28
States / cities: Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions: MK-2225, Placebo; Biological
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Advanced Solid Tumors
Interventions: Vabametkib, Lazertinib; Drug
Lead sponsor: Abion Inc; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more

Conditions: Prostate Cancer
Interventions: Investigators choice of SoC, AAA817; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Wounds and Injuries
Interventions: Altrazeal (R) Transforming Powder Dressing, Standard of Care burn dressing; Device · Other
Lead sponsor: ULURU Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Orange, California • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Avelumab, Chemoradiation; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 139
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more

Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: Neonc Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more

Search by objective public record fields.

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

Optimizing PrEP Uptake and Adherence Among Male Sex Workers

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

A Study With Imlifidase in Anti-GBM Disease

Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis